Introduction
Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) comprises 2-5% of pediatric ALL (pALL), a considerable proportion, 15-25%, of adult ALL (aALL), whereas this translocation is a pathognomic feature for chronic granulocytic leukemia (CGL). 1, 2 The existence of lymphoid blastic crisis (LBC) of CGL with clinically silent chronic phase poses particular difficulties for the differentiation of this entity from de novo Ph-positive ALL. One feature of CGL-LBC is that after complete remission the disease reverts to chronic phase, whereas the other is unequivocally of uncommitted stem cell origin. 3, 4 It has been known for a long time that if an apparently de novo Ph+ ALL patient achieves complete remission and the disease reverts to the chronic phase, the percentage of Ph-positive cells remains high. Alternatively, in those patients who do not revert to chronic phase after complete remission, the Ph chromosome is often no longer detected in the bone marrow for variable periods of time. If partial remission is achieved then there is a correlation between the percentage of bone marrow blasts and the percentage of Ph-positive metaphases. On this basis speculation has been justified that those Ph-positive ALLs which revert or do not revert to chronic phase might be different in the level of hemopoiesis at which the chromosome aberration has arisen and the clonal proliferation been triggered. 3 However, the issue of which level of hemopoiesis the de novo Ph-positive ALL arises at is controversial in the light of those 43 Ph-positive ALL patients which have been lineage analyzed to our knowledge. 1, [5] [6] [7] [8] [9] [10] [11] [12] [13] Whereas both multilineage and lymphoid restricted Ph-positive ALLs have been described among these cases, Schenk et al 13 have recently published the largest series of lineage analyzed Ph-positive de novo ALL patients and all of them were assigned as having multilineage disease.
To gain further insight into this controversial issue we have analyzed 17 Ph-positive ALL patients. Lineage-specific chromosomal change was investigated by morphology and fluorescent in situ hybridization (FISH) using a combined light and fluorescent microscopical image analysis. Using this approach, we obtained a result which is opposite to the latest and largest investigation in this research field.
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Materials and methods
Patients
Cell lineage-specific genetic features of six children and 11 adults presented as acute lymphoblastic leukemia with no history of previous chronic myeloproliferative disorder were analyzed. Only one patient (No. 5) had moderate hepatosplenomegaly at admission, but immature or intermediate myeloid elements were not evident in the peripheral blood in any of the patients.
Molecular investigations RNA isolation:
RNA was isolated from 2 × 10 7 white blood cells using TRIZOL reagent (Gibco BRL, Gaithersburg, MD, USA) according to the manufacturer's instructions. RNA precipitate was desolved in DEPC-treated water at a concentration of 0.3 g/l.
Reverse transcription:
The reverse transcription was performed in a 10 l buffer containing 3.0 mmol/l MgCl 2 , 75 mmol/l KCl, 50 mmol/l Tris-HCl, pH 8.3 (Oncor, Gaithersburg, MD, USA), 150 nmol/l of the antisense primers of each PCR reaction (see below), 500 mol/l of each dNTPs (Life Technologies, Gaithersburg, MD, USA), 2.5 U MMLV-RT, (Oncor) and 0.6 g of total cellular RNA, at 37°C, for 1 h.
Polymerase chain reactions:
The M-bcr PCR assay was performed according to Lion et al. 14 The nested version was chosen using the 5Ј-TTCAGAAGCTTCTCCCTG-3Ј sense and the 5Ј-CTCCACTGGCCACAAAAT-3Ј antisense primers for the first reaction, as well as 5Ј-GTGAAACTCCAGACTGTC-3Ј and 5Ј-CAACGAAAAGGTTGGGGT-3Ј for the second one. The m-bcr PCR assay was done as described by Nakamura et al. 15 Sense primer: 5Ј-GTT GTC GTG TCC GAG GCC AC-3Ј, antisense primer: 5Ј-GCT CAA AGT CAG ATG CTA CT-3Ј. The quality of the RNA isolate was assessed by the amplification of abl exons 2-3 according to Hermans et al, 16 but using 2.0 mmol/l MgCl 2 concentration in the buffer and forty cycles of 94°C 1 min, 50°C 1 min, 72°C 1 min. The sense primer in this assay was: 5Ј-CAGCGGCCAGTAGCATCTGACTT-3Ј, whereas the antisense primer was 5Ј-TGTGATTATAGCCTAA-GACCCGGAG-3Ј.
Fluorescent in situ hybridization on interphase cells (FISH-IPC) for bcr-abl rearrangement:
Cytocentrifuge preparations or smears made from buffy coat cells of peripheral blood samples and stained either for hematoxylin-eosin or May-Grü nwaldGiemsa were postfixed in 50% acetic acid and air-dried. For the interphase detection of the Philadelphia chromosome the commercial LSI bcr-abl dual color DNA kit (Vysis, Downers Grove, IL, USA) was used according to the instructions of the manufacturer. After hybridization and development the slides were mounted with DAPI/Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). In interphase nuclei of normal cells, the probe signals appear as two distinct dots of each color (bcr -SpectrumGreen; ablSpectrumOrange). In Ph-positive cells the juxtaposition of the bcr and abl gene sequences results in coalescence of the green and red fluorescent signals giving a yellow fusion signal which indicates the presence of the translocation. A Zeiss Axioskop epi-illumination fluorescent microscope (Carl Zeiss, Jena, Germany) equipped with a triple bandpass filter VY-DGO (Vysis) was used for evaluation of the preparations and counting the signals. The false positivity was investigated in 500 peripheral blood cells of three healthy individuals and the 3.4% cut-off level for this assay was determined as the mean false positivity + 2 s.d.
Cell lineage analysis by FISH-IPC and imaging microscopy
Cytopreparations or smears of peripheral blood leukocytes were stained for either hematoxylin-eosin or May-Grü nwaldGiemsa and investigated under the Zeiss Axioskop combined transmission light and epi-illumination fluorescent microscope equipped with a stepper motor, a 3-CCD color camera, model HV-C20 (Hitachi Denshi, Tokyo, Japan) and a triple bandpass filter as above. Images of fields with defined X-Y-Z coordinates, containing mixed cell populations were acquired. FISH-IPC procedure for bcr-abl rearrangement was then carried out on each slide followed by relocation of the previously captured fields in fluorescent mode. FISH signals were analyzed in nuclei with intact morphology as defined on the DAPI image. Nuclei with the presence or lack of the translocation were identified to be lymphoblasts, mature myeloid elements, reactive lymphocytes and erythroid precursors by comparison of the fluorescent images with the stored transmission light microscopical ones. In this way, on average, 150 cells per slides could be analyzed with 32 to 93% being lymphoblasts by morphology.
Flow cytometry
Three-color flow cytometry was used, and the measurements were performed by means of a Becton Dickinson FACSort Leukemia flow cytometer (BDIS, San Diego, CA, USA). To determine the percentage of the blastic cell populations CD10-FITC, CD34-RPE and CD45-RPE-Cy5 (DAKO, Glostrup, Denmark) antibodies were applied to 10 6 cells. Immunolabelling and processing of samples were done according to the manufacturers' instructions. Data of 10 000 events from each sample were acquired and evaluated by means of the CellQuest software (BDIS). The ratio of the blastic cells was determined on the CD45 vs SSC plot as well as by the CD10 and CD34 positivity. Among these figures the highest value was considered to represent best the percentage of blasts.
Results
We have analyzed six pediatric and 11 adult ALL patients with no history or cytological hallmarks of a previously existing chronic myeloproliferation. Patients' data are summarized in Table 1 . We have found among these patients 14 common types of ALL, the other three being positive only for CD19 and 34. All the patients' peripheral blood cells exhibited the bcr- These observations indicate that except for three patients the disease was restricted to the lymphoid stem cell compartment, whereas the three patients with multilineage involvement proved to be CGL-LBC with a clinically silent chronic phase. We have summarized the lineage involvement data, types of translocation (wherever available) and techniques used in those Ph-positive ALL cases which have been lineage analyzed to our knowledge (Table 2 ). Our review of the literature achieved a slightly different result as compared to that published recently. 13 
Discussion
The relationship between Ph+ ALL and chronic granulocytic leukemia (CGL) in lymphoblastic crisis (LBC) has been the subject of debate since Ph+ ALL was first described by Propp and Lizzi. 17 CGL-LBC following a clinically silent chronic phase can hardly be distinguished from truly de novo Ph+ ALL. The features supporting the latter are: (1) the presence of chromosomally normal cells accompanying the Ph+ clone; (2) the lack of an overt chronic phase; (3) higher frequency of clonal evolution at diagnosis, ie more frequent cytogenetic abnormalities additional to the Ph chromosome.
1 Also, it has been known for a long time that after achieving remission Leukemia some of Ph+ ALLs revert to chronic phase, but in those which do not revert to chronic phase, the percentage of blastic cells remains proportional with that of the Ph+ metaphases. 3 Molecular analyses revealed that Ph translocation in ALL results in a bcr-abl protein of 190 kDa molecular weight that is distinct from the bcr-abl protein of 210 kDa molecular weight found in Ph+ CGL and also in its lymphoblastic crisis. 18, 19 On this basis it has been suggested that the Ph+ ALL with M-bcr type of translocation might be the CGL-LBC of uncommitted stem cell origin whereas that with the m-bcr type of translocation would be de novo ALL with lymphoid lineage restriction. Further investigations have revealed, however, that both types of translocation occur in the de novo ALLs with a definite preponderance of m-bcr type in the pediatric group. [20] [21] [22] There are two prognostically different groups in the apparently de novo Ph+ ALL, one with 35-47 months and the other with 4-8 months survival, respectively. 1, 12 No association between the type of translocation and the prognosis could be proved, so the cell of origin and the extent of lineage involvement have been investigated to clarify the nature of this prognostic heterogeneity. 23, 24 This revealed that Ph+ ALL patients with significantly longer survival fell into the multilineage category whereas those with poor prognosis proved to have lymphoid restricted diseases. Furthermore, based on the analysis of their own patients and reviewing cases reported by others, Anastasi et al 12 concluded that the multilineage diseases were, in fact, CGL that initially presented in LBC. We are aware of 43 lineage analyzed Ph+ ALL cases; later five of them were claimed to be CGL-LBC because of a reversal to chronic phase. [5] [6] [7] [8] [9] [10] [11] [12] [13] In these cases lineage involvement was determined using such techniques as in vitro colonies and conventional cytogenetics, cell separation and Southern blot or FISH as well as morphology and FISH. Discounting those five patients we have 38 Ph+ ALLs, half of them with stem cell origin and the rest with lymphoid lineage restriction. In 26 patients the type of translocation was also defined. Among the pediatric ALL cases no M-bcr type of translocation was claimed in either lineage group whereas both types of translocation occurred in the lymphoid as well as the multilineage groups among adults. Looking at this collection and considering the equal number of patients in the two lineage groups one might be suprised that the largest series are contradictory to each other. It is hard to explain, merely on a statistical basis, the reason why equal distribution of the two lineage groups is not represented in series where nine as well as 17 (this study) eight and five patients were analyzed. 8, 12, 13 More accurately, the last three studies proved that Ph+ ALL cases are lymphoid restricted except for those which reverted to chronic phase. This contradicts the results of the first study where all the cases exhibited a multilineage involvement. As an explanation for this controversial situation one might speculate about technical problems, such as minor contamination in cell fractions which would be amplified by molecular techniques. Moreover, if a patient dies during the early remission induction period or allogeneic bone marrow transplantation takes place in the first early complete remission, it becomes impossible to define the disease later on as truly de novo disease or CGL-LBC with silent chronic phase. This was the case in eight of our 17 patients, however, they exhibited lymphoid restriction, so their truly de novo nature might not be questionable.
In summary, we have analyzed the largest series of Ph+ ALL patients using combined morphology and FISH technique, a process which, in the future, is likely to be the most accurate procedure to investigate lineage involvement. We found multilineage involvement in only those patients who reverted to chronic phase, thus they should be considered as CGL-LBC. We have not obtained evidence for the existence of the so called 'Ph+ stem cell ALL'. 1 In this way our findings are consistent with those of Anastasi et al, 12 who performed a study using the same methodology as we did, however, we additionally found breakpoint heterogeneity in the lymphoid restricted cases. Prognosis and treatment strategies of CGL-LBC as well as truly de novo Ph-positive ALL are considerably different, therefore lineage analysis in this disorder is critically important and should be incorporated into the routine diagnostic procedures. Further studies on lineage involvement are needed to complete the rather scant literature in order to clarify the biological nature of Ph+ ALL.
